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eplerenone decreased cardiovascular mortality and deaths from
any cause by 15% (p = 0.008) in patients with acute myocardial
infarction complicated by left ventricular dysfunction and heart
failure. An economic evaluation was performed to asses the
cost-effectiveness of epleronone vs. placebo through patient life-
time in the Spanish setting. METHODS: The cost-effectiveness of
eplerenone in cost per Life-Year (LYG) and Quality-Adjusted-
Life-Years (QALY) gained compared to placebo was estimated.
Efﬁcacy data from EPHESUS study during the 16 month
follow-up period were used. Survival data beyond trial period
were estimated from the Framingham Heart Study Registry. The
study was carried out from societal perspective; therefore, only
direct medical costs where included. Drug acquisition costs were
priced at AWP (average wholesale price), €2007. Costs were
obtained from Spanish databases. Costs and effects were dis-
counted 3% annually. Sensitivity analyses were carried out based
on alternative life-years gained estimates from the Saskatchewan
Health database and Worcester Heart Attack Registry Data,
(0.0636 and 0.1337 respectively). RESULTS: The number of
LYG with eplerenone was 0.1014 based on Framingham. Cost
was €1016.90 higher over the trial period in the eplerenone arm
because of drug cost (€1,164.07). The Framingham incremental
cost-effectiveness ratio (ICER) of eplerenone compared to
placebo was 10,030€ per LYG and 15,047€ per QALY gained.
Sensitivity analyses showed eplerenone was efﬁcient under
alternative life expectancy estimates: €15,99€ per LYG with
Saskatchewan and €7,60€ per LYG with Worcester. CONCLU-
SIONS: Selective aldosterone blockade with eplerenone is a cost-
effective strategy in post-AMI patients with heart failure in Spain.
In addition to standard therapy, eplerenone prevents events,
saves hospitalization resources and improves survival among
these patients.
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OBJECTIVES: Clopidogrel has shown to be cost-effective to
prevent ischemic events in non-ST segment elevation acute coro-
nary syndromes (NSTEACS). This study is intended to assess
the cost-effectiveness of clopidogrel in long-term treatment of
ST-segment elevation myocardial infarction (STEMI) in Spain.
METHODS: A combined decision tree and Markov model was
constructed. Efﬁcacy data was obtained from CLARITY and
COMMIT trials for the ﬁrst month, and the “CAPRIE-like”
cohort of CHARISMA trial (months 2–12). The risks of death,
myocardial infarction, and stroke in an untreated population and
long-term survival after all events were derived from the Swedish
Hospital Discharge and Cause of Death register. A payer perspec-
tive was chosen for the analysis, using local costs. Effectiveness
was measured as the number of life-years gained (LYG) with
clopidogrel treatment. Costs and effects were discounted at 3%.
RESULTS: The difference in stroke rates was more pronounced
in CLARITY (0.9% vs. 1.7% and 0.55% vs. 0.62% in the
CLARITY and COMMIT respectively) and thus facilitates
important cost savings. In two patient cohorts with the same
characteristics and event rates as in the CLARITY and COMMIT
population, treatment with clopidogrel for up to 1 year opposed
to treatment with ASA resulted in ICERs (€/LYG)of: in
CLARITY cohort €397 and in COMMIT cohort €2927. CON-
CLUSIONS: Treatment of STEMI patients with clopidogrel
appeared to be cost-effective in long-term with predicted ICERs
below generally accepted threshold value of €30,000/LYG.
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OBJECTIVES: Abdominal Aortic Aneurysm (AAA) is deﬁned as
a localized dilatation of aortic vessel. It’s predominantly asymp-
tomatic, but represents a chronic degenerative condition associ-
ated with life-threatening risk of rupture. The early diagnosis of
AAA, i.e. before its ruptures, is therefore important and ultra-
sound examination is a simple and effective method for this.
To asses beneﬁt of screening in Italy we developed a cost-
effectiveness Markov model comparing screening vs non screen-
ing scenario. METHODS: We considered a patient cohort
composed of 65 years old men screened for AAA in the Italian
NHS perspective and compared it to a non-screened population.
We collected data both from literature and from a real screening
program that is on-going in San Martino Hospital in Genova.
The following health states were distinguished: no AAA,
unknown small-AAA (3–3.9 cm), followed-up small-AAA (1
year), unknown medium-AAA (4–4.9 cm), followed-up medium-
AAA (6 months), unknown large-AAA (>5 cm), elective repair,
emergency repair, electively repaired AAA, emergency repaired
AAA, rejected large AAA and death. Transition between health
states were simulated using 6-month cycles. Incremental cost per
life year saved was calculated for a 35-year time horizon and
applying a 3% discount rate to both cost and beneﬁts. RESULTS:
Considering an attendance rate of 70%, the individual cost per
invited subject was €104.42. 0.024 additional life years was
gained per patient in the screened cohort, corresponding to an
ICER of €4363/LYS. Univariate and multi-variate sensitivity
analyses were performed for all parameters. The results were not
sensitive to changes in parameters and suggest that screening for
AAA is cost-effective with a probability approaching 100%
based on a willingness-to-pay threshold of €30,000. CONCLU-
SIONS: Similarly to economic evaluations developed in other
countries like UK, Canada, etc, the setting up of a screening
program for AAA can be considered to be cost-effective in the
Italian NHS perspective.
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OBJECTIVES: Recent progress has enabled physicians to meet
the challenge of syncope diagnosis and provide faster and better
guided treatment to the patient. Syncope investigation tradition-
ally included loosely-deﬁned combinations of ECGs, Holter
Monitors, Tilt Tests, EP Studies and Imaging Diagnostics. While
tests were being performed, patients remained at risk of death,
falls and fractures. We wanted to examine the potential cost-
effectiveness of adding an Implantable Loop Recorder to the
traditional clinical pathway. Clinical evidence increasingly dem-
onstrates that ILR-enhanced diagnostics may enable physicians
to achieve more clear diagnoses, at a fraction of the time.
METHODS: We developed a decision-analytic model in
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Microsoft Excel. The model compares the cost-effectiveness of
standard diagnostics with the one of ILR-enhanced diagnostic
pathways. Number of positive diagnoses was used as the
outcome measure. The number of diagnostic tests per patient and
the yield of each test were found in published clinical literature.
Cost data were taken from Dutch national sources. Sensitivity
analyses were conducted using Monte Carlo Simulation.
RESULTS: Literature and sensitivity analyses clearly show that
the ILR-based pathway has a signiﬁcantly higher capacity of
providing a correct diagnosis (33.7% vs. 4.1%) within the same
timeframe. The cost per diagnosis in the ILR-based pathway was
slightly higher than the cost per diagnosis of more conventional
care (approximately €1200 more needed per diagnosis with
ILRs). CONCLUSIONS: ILRs can be considered an established,
safe and efﬁcient addition to syncope diagnostics. They provide
physicians with excellent diagnostic yield, enabling timely and
correct treatment of patients whose condition could remain undi-
agnosed. Cost per diagnosis demonstrates the cost-effectiveness
of their use. Potentially, ILRs can also reduce time-to-diagnosis
and operational expenditure of the hospital. Should that be the
case, ILRs can be even more cost-effective while enabling more
patients to get life-saving treatment faster.
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OBJECTIVES: The IDEAL trial (Incremental Decrease in End
Points through Aggressive Lipid Lowering) was an open label,
blinded endpoint evaluation of 8888 patients with history of
acute myocardial infarction (MI) who were randomized to ator-
vastatin 80 mg or simvastatin 20–40 mg. The median follow-up
was 4.8 years. Major coronary events (coronary death, hospital-
ization for MI, or resuscitated cardiac arrest) were reduced by
11%, (hazard ratio [HR], 0.89; 95% conﬁdence interval [CI],
0.78, 1.01; P = 0.07). There was a 16% relative risk reduction in
all cardiovascular events (HR 0.84, 95% CI: 0.76 to 0.91). The
objective of the study was to asses the cost-effectiveness ratio of
atorvastatin 80 mg versus simvastatin 20–40 mg among patients
with history of coronary heart disease (CHD) in Spain taking
into account all CV events. METHODS: A within trial pharma-
coeconomic analysis was developed to estimate cost per event
avoided. Direct (hospitalization, drugs) and indirect costs (lost
production due to work absence) were included in the model. To
estimate the cost of these hospitalizations, drug reimbursement
group (DRG) was used. Effectiveness was estimated as the
number of events in both arms. RESULTS: After 4.8 years,
treatment with intensive atorvastatin could avoid 1 in 6 CV
events compared with moderate simvastatin therapy among
patients with CHD. Despite atorvastatin having a higher drug
cost, this was offset by lower cost of reduced hospitalizations and
work days lost for patients receiving atorvastatin treatment.
Using Spanish costs the incremental cost for atorvastatin to avoid
an event was €15,168. CONCLUSIONS: In a cohort of 8888
Spanish patients with CHD one cardiovascular event could be
prevented for cost of €1520 euros/patient over 4.8 years. Based
on these results, it appears that even in a low cost generic market,
high dose atorvastatin is a good option compared to standard
therapy with simvastatin.
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OBJECTIVES: The timely diagnosis of deep venous thrombosis
(DVT) is critical because this disorder can be life threatening.
However, referring all patients suspected of DVT for ultrasound
(US) testing is inefﬁcient since 80 to 90%of those referred have no
DVT. Therefore, we investigated the cost-effectiveness of a diag-
nostic strategy based on a point of care d-dimer test combined
with a clinical decision rule that was documented to be safe in
primary care (AMUSE study). METHODS: A model based cost-
effectiveness analysis was conducted in conjunction with a recent
multi centre prospective diagnostic study (AMUSE, N = 1002). A
Markov model with a ﬁve year time horizon was used to compare
the AMUSE strategy to two hospital based strategies: ultrasound
for all and a hospital decision rule. Probabilities were derived from
AMUSE and the literature. Societal costs and health state utilities
were used. One way and probabilistic sensitivity analyses were
conducted. Cost-effectiveness acceptability curves were con-
structed. RESULTS: The AMUSE strategy has both slightly lower
costs and less quality adjusted life years (QALYs) than both
hospital based strategies. The ultrasound for all strategy has the
highest costs andQALYs, but is not cost-effective as compared the
hospital decision rule strategy. The AMUSE strategy compared to
the hospital decision rule strategy resulted in a mean saving
of €138, and a mean QALY loss of 0.002. The incremental
cost-effectiveness ratio is €56,436 per QALY lost. The cost-
effectiveness acceptability curves show that the AMUSE strategy
has the highest probability of being cost-effective, even exceeding
ceiling ratios of €80,000 per QALY. CONCLUSIONS: The
AMUSE strategy to exclude DVT in primary care is not only safe,
but also has the highest probability of being cost-effective as
compared to hospital based strategies to diagnose DVT.
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OBJECTIVES: Hypertension and dyslipidemia are highly preva-
lent, often concurrent and act independently, as well as together,
to increase the risk of cardiovascular disease (CVD). This study
sought to investigate the cost-effectiveness of a single-pill com-
bination of amlodipine/atorvastatin (SPAA) for the primary pre-
vention of CVD (comprising coronary heart disease and ischemic
stroke) in Korea. METHODS: A Markov model was developed
with four health states: ‘Alive without CVD’, ‘Alive with CVD’,
‘Dead from CVD’ and ‘Dead from non-CVD causes’, The model
cohort used comprised 171 Korean adults aged 55 years from
the 2005 Korea National Health and Nutritional Examination
Survey (KNHANES) who were CVD-free but met current
Korean criteria for treatment with SPAA. Follow-up was simu-
lated for 40 years. Cardiovascular risk was estimated for each
subject individually using a published, multivariable, Asian-
speciﬁc equation. With subsequent cycles, the cardiovascular
risk proﬁle of each subject was updated. Data regarding the
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